Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY2944876 versus once-weekly exenatide and placebo in adults with type 2 diabetes mellitus
2013-003552-21Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2014
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised trial of pegapamodutide in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change from baseline in hemoglobin A1c at 12 weeks. Started Mar 2014; status: completed.
02
Drugs
pegapamodutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2013-003552-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003552-21.